Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) had its price objective reduced by equities research analysts at Chardan Capital from $5.50 to $4.00 in a research report issued to clients and investors on Thursday. The firm currently has a “buy” rating on the stock. Chardan Capital’s price objective suggests a potential upside of 257.14% from the company’s current price.

Separately, ValuEngine cut Aralez Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

Aralez Pharmaceuticals (ARLZ) opened at 1.12 on Thursday. The firm’s market cap is $73.75 million. Aralez Pharmaceuticals has a 12-month low of $1.09 and a 12-month high of $6.80. The firm has a 50-day moving average price of $1.32 and a 200 day moving average price of $2.17.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.01. Aralez Pharmaceuticals had a negative return on equity of 66.74% and a negative net margin of 133.92%. The business had revenue of $27.62 million for the quarter, compared to the consensus estimate of $21.37 million. During the same quarter in the previous year, the business posted ($0.27) EPS. The company’s revenue for the quarter was up 119.6% on a year-over-year basis. Equities research analysts forecast that Aralez Pharmaceuticals will post ($1.56) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/08/10/chardan-capital-lowers-aralez-pharmaceuticals-inc-nasdaqarlz-price-target-to-4-00.html.

In other news, Director Arthur S. Kirsch acquired 50,000 shares of Aralez Pharmaceuticals stock in a transaction dated Wednesday, June 14th. The stock was bought at an average price of $1.17 per share, for a total transaction of $58,500.00. Following the completion of the acquisition, the director now directly owns 206,609 shares in the company, valued at approximately $241,732.53. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jason Aryeh sold 388,685 shares of the business’s stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $1.44, for a total value of $559,706.40. Following the sale, the director now owns 15,000 shares of the company’s stock, valued at approximately $21,600. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 569,115 shares of company stock valued at $790,719. Corporate insiders own 6.70% of the company’s stock.

Several large investors have recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its stake in shares of Aralez Pharmaceuticals by 2.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 314,224 shares of the company’s stock worth $1,386,000 after buying an additional 7,014 shares in the last quarter. Norges Bank purchased a new stake in shares of Aralez Pharmaceuticals during the fourth quarter worth about $665,000. Isthmus Partners LLC boosted its stake in shares of Aralez Pharmaceuticals by 4.9% in the first quarter. Isthmus Partners LLC now owns 153,102 shares of the company’s stock worth $328,000 after buying an additional 7,110 shares in the last quarter. Elk Creek Partners LLC boosted its stake in shares of Aralez Pharmaceuticals by 13.3% in the first quarter. Elk Creek Partners LLC now owns 2,488,475 shares of the company’s stock worth $5,325,000 after buying an additional 292,420 shares in the last quarter. Finally, KCG Holdings Inc. purchased a new stake in shares of Aralez Pharmaceuticals during the first quarter worth about $310,000. Institutional investors own 35.61% of the company’s stock.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.